TriangleNCT00833417 · OUTCOME
Overall Survival
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEDIAN
- Unit
- Months
- Interval / dispersion
- 95% Confidence Interval
- Time frame
- From the initial dose of study drug until death from any cause (up to the clinical cutoff date of 30 May 2013, up to 4 years)
What was measured
Overall survival was defined as the time from the initial dose of vismodegib until death from any cause.
Analysis population: Efficacy-evaluable population: All treated patients for whom the independent pathologist's interpretation of archival tissue or baseline biopsies was consistent with basal cell carcinoma.
Groups in this outcome
Metastatic Basal-Cell Carcinoma
Patients received vismodegib 150 mg orally once daily until disease progression; intolerable toxicity, most probably attributable to vismodegib; or withdrawal from the study.
Locally Advanced Basal-Cell Carcinoma
Patients received vismodegib 150 mg orally once daily until disease progression; intolerable toxicity, most probably attributable to vismodegib; or withdrawal from the study.
| Group | Source count |
|---|---|
| Metastatic Basal-Cell Carcinoma | 33 |
| Locally Advanced Basal-Cell Carcinoma | 63 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Metastatic Basal-Cell Carcinoma | 33.4 | Not reported | 18.10 | NA | The upper limit of the 95% confidence interval could not be estimated because of the small number of patients who had an event (17 patients had died by the cutoff date). |
| Locally Advanced Basal-Cell Carcinoma | NA | Not reported | NA | NA | The median and 95% confidence interval could not be estimated because of the small number of patients who had an event (13 patients had died by the cutoff date). |
Complete source fields
- classes
- categories
- measurements
- comment
- The upper limit of the 95% confidence interval could not be estimated because of the small number of patients who had an event (17 patients had died by the cutoff date).
- group Id
- OG000
- lower Limit
- 18.10
- upper Limit
- NA
- value
- 33.4
- comment
- The median and 95% confidence interval could not be estimated because of the small number of patients who had an event (13 patients had died by the cutoff date).
- group Id
- OG001
- lower Limit
- NA
- upper Limit
- NA
- value
- NA
- denoms
- counts
- group Id
- OG000
- value
- 33
- group Id
- OG001
- value
- 63
- units
- Participants
- description
- Overall survival was defined as the time from the initial dose of vismodegib until death from any cause.
- dispersion Type
- 95% Confidence Interval
- groups
- description
- Patients received vismodegib 150 mg orally once daily until disease progression; intolerable toxicity, most probably attributable to vismodegib; or withdrawal from the study.
- id
- OG000
- title
- Metastatic Basal-Cell Carcinoma
- description
- Patients received vismodegib 150 mg orally once daily until disease progression; intolerable toxicity, most probably attributable to vismodegib; or withdrawal from the study.
- id
- OG001
- title
- Locally Advanced Basal-Cell Carcinoma
- param Type
- MEDIAN
- population Description
- Efficacy-evaluable population: All treated patients for whom the independent pathologist's interpretation of archival tissue or baseline biopsies was consistent with basal cell carcinoma.
- reporting Status
- POSTED
- time Frame
- From the initial dose of study drug until death from any cause (up to the clinical cutoff date of 30 May 2013, up to 4 years)
- title
- Overall Survival
- type
- SECONDARY
- unit Of Measure
- Months
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice